The slides from the IHS Healthcare and Pharma webcast held on 15 November, 2012 titled European Turmoil 2012: A Review of Drug Prices and Market Access Across Europe
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Carlos Betancur Gálvez
Valery Paris, analista senior de Política Sanitaria, División de Salud, de la Organización de Desarrollo y Cooperación Económica (OCDE), ha destacado en su ponencia la importancia de considerar en la asignación de los precios de los medicamentos “los beneficios más allá del sector de la salud”, en referencia al coste de oportunidad y a otras variables económicas de lo que supone la entrada de un medicamento en un determinado mercado. París también ha señalado la dificultad de establecer una política común de asignación de precios en los diferentes países europeos: “Los países no siempre llegan a un acuerdo, por ejemplo, en el grado de innovación de nuevos productos”.
The presentation summarises recent changes implemented or being discussed in pricing and reimbursement/HTA systems in France, Germany and the UK. In Germany and France, the emphasis of the recent reforms is centred around the evidence requirements and, in particular, the use of comparator and head-to-head trials. In the UK, however, VBP is about the weighting given to the evidence and the social value of a drug. Overall, emphasis is increasing on 'proving' innovation and/or an additional health benefit as a precondition for a price higher than competitors.
Kiriasis Savvas, EIPG Greek Delegate
Presentation at Malta Qualified Persons Association-European Industrial Pharmacists Group-University of Malta joint seminar “The Successes And Challenges Of Today’s Pharmaceutical Industry”, Malta 2008.
APIFARMA, the Portuguese pharmaceutical industry assocation, holds a series of conference throughout they year. OHE's Jorge Mestre-Ferrandiz, an expert on pricing and reimbursement (P&R) in Europe, was the lead speaker at the October 2014 conference on access to innovation. His presentation covers existing and potential approaches to evaluating new medicines as a condition for P&R in France, Germany and the UK.
Pharma Maket Access - Southeast Europe & TurkeyZdravko Mauko
Key figures about pharmaceutical market access in southeast Europe and Turkey. Summary about market authorisations, pricing and reimbursement for Croatia, Serbia, Bosnia and Herzegovina, Macedonia, Kosovo, Albania, Bulgaria, Romania and Turkey
Pharmaceutical pricing in european countries - Valérie Paris - 22-01-15Carlos Betancur Gálvez
Valery Paris, analista senior de Política Sanitaria, División de Salud, de la Organización de Desarrollo y Cooperación Económica (OCDE), ha destacado en su ponencia la importancia de considerar en la asignación de los precios de los medicamentos “los beneficios más allá del sector de la salud”, en referencia al coste de oportunidad y a otras variables económicas de lo que supone la entrada de un medicamento en un determinado mercado. París también ha señalado la dificultad de establecer una política común de asignación de precios en los diferentes países europeos: “Los países no siempre llegan a un acuerdo, por ejemplo, en el grado de innovación de nuevos productos”.
The presentation summarises recent changes implemented or being discussed in pricing and reimbursement/HTA systems in France, Germany and the UK. In Germany and France, the emphasis of the recent reforms is centred around the evidence requirements and, in particular, the use of comparator and head-to-head trials. In the UK, however, VBP is about the weighting given to the evidence and the social value of a drug. Overall, emphasis is increasing on 'proving' innovation and/or an additional health benefit as a precondition for a price higher than competitors.
Kiriasis Savvas, EIPG Greek Delegate
Presentation at Malta Qualified Persons Association-European Industrial Pharmacists Group-University of Malta joint seminar “The Successes And Challenges Of Today’s Pharmaceutical Industry”, Malta 2008.
APIFARMA, the Portuguese pharmaceutical industry assocation, holds a series of conference throughout they year. OHE's Jorge Mestre-Ferrandiz, an expert on pricing and reimbursement (P&R) in Europe, was the lead speaker at the October 2014 conference on access to innovation. His presentation covers existing and potential approaches to evaluating new medicines as a condition for P&R in France, Germany and the UK.
Pharma Maket Access - Southeast Europe & TurkeyZdravko Mauko
Key figures about pharmaceutical market access in southeast Europe and Turkey. Summary about market authorisations, pricing and reimbursement for Croatia, Serbia, Bosnia and Herzegovina, Macedonia, Kosovo, Albania, Bulgaria, Romania and Turkey
Thomas Müller, MD & Pharmacist, Head of Pharmaceuticals Dept Federal Joint Committee.
Pharma Pricing & Market Access Congress 2017
22 February 2017
London
Global HTA and pricing mechanisms
What can we learn about national medicines pricing and procurement?
Led by Janssen UK
Day One, Pop-up University 3, 16.00
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run.
Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London)
Event: HTAi 2019 Annual Meeting
Date: 18/06/2019
Location: Cologne, Germany
Is European market access becoming an incubator for rare disease development?...KateBenson18
FIECON's white paper 'Is European market access becoming an incubator for rare disease development?' explores the hypothesis that successful commercialisation in Europe is the biggest commercial opportunity for orphan drug manufacturers right now.
Hampered with faltering economies, squeezed budgets
and aging populations, the healthcare systems of Europe’s
major markets are firmly focused on providing cost-effective
outcomes. Although each country has specific market access
requirements, Health Technology Assessment (HTA) has
become an essential input into pricing and reimbursement
decisions and clinical guidance on the use of innovative
technologies across Europe.
Though HTA practices differ across and within national
boundaries, specific themes have emerged.In particular,
demands for evidence of clinical and/or economic benefit on
new health technologies are increasing.
Pricing and reimbursement negotiations are becoming
increasingly difficult, as cost-containment strategies—
including reference pricing, limiting reimbursement for
drugs assessed to lack cost-effectiveness, and retroactively
assessing drugs already on the market—are being
implemented in various ways across Europe.
This document has been put together with our leading market access experts compiled together from number of primary research published by our team recently.
Feel free to reach out on msheikh@teamdrg.com if you would like to talk more about our analysis in this space and how we could support with any specific questions you may have.
About US: DRG's Research and Data portfolio delivers industry-leading primary research and insights. We provide our customers with a baseline for market intelligence.
This presentation by Duncan Matthews was made during the Workshop on Recent Challenges in Competition and IP in Pharmaceutical Markets on 26 February 2019. More material on the workshop can be found at www.oecd.org/daf/competition/workshop-on-recent-challenges-in-competition-and-ip-in-pharmaceutical-markets.htm
Jan 31, 2018 How to Ensure Patient-Centred Pharmacare is Cost-Effective Healthcare
A Consultation on Patented Medicine Prices Review Board & Biologic Medicines
This presentation by Italy was made during a workshop on “Recent Challenges in Competition and IP in Pharmaceutical Markets” held by the OECD in Paris on 26 February 2019. More papers and presentations on the topic can be found out at oe.cd/2tD
The Regulatory Policy Institute, based in Oxford, holds an annual conference on competition and regulation. At this year’s conference, OHE’s Jon Sussex described how the prescription medicines market in England is regulated for innovation.
The regulatory problem for the pharmaceutical market is different from that for utilities markets, transport, financial services and indeed markets for all other types of goods and services. The source of the regulatory problem for prescription medicines in the NHS is that the consumer (patient) neither decides which medicine is prescribed nor is responsible for paying for it. For other goods and services, the consumer decides and pays, as well as consumes. In the pharmaceutical market under the NHS, it is the payer who effectively decides the value of an innovation, not the patient.
The cost and risk in drug development are high. To determine how best to target its R&D efforts, the pharmaceutical industry needs clear signals about what innovation the health care payer, the NHS, values. The recent history of such signalling has been dominated in England by the actions of the National Institute for Health and Care Excellence (NICE), whose assessments also have considerable influence internationally. Moreover, although England represents only 2% of the world pharmaceutical market, its prices are use as a reference for pricing in other markets.
How NICE expresses the value of medicines can be viewed as a mean of regulating innovation. NICE always has based its decisions about value on the incremental cost to the tax-funded health and social care services of the additional quality-adjusted life years a new medicine offers to patients. During the last year, NICE has been consulting on ways to broaden its assessment of value, particularly on whether to take account of the burden of disease and wider societal impacts beyond QALYs. The decisions have not yet been made and the signal to potential pharmaceutical innovators remains fuzzy.
Join Bill Dempster & guests Louise Binder & Martine Elias as they discuss the updates to the federal pharmaceutical price reform proposal, how patient leaders are responding and what steps they are taking to ensure that patients are being heard by decision makers.
This presentation by the French Competition Authority was made during a workshop on “Recent Challenges in Competition and IP in Pharmaceutical Markets” held by the OECD in Paris on 26 February 2019. More papers and presentations on the topic can be found out at oe.cd/2tD
Following the cancellation of most of the federal government’s proposed changes to the Patented Medicine Prices Review Board’s regulations, questions remain about how the Board will proceed in the future. The webinar will review the original changes and the one that remains. The topic will be discussed through the lens of a global pharmaceutical executive’s decision-making about whether to launch a new rare disorder drug in Canada in the next 12-18 months. Finally, we will chat about the uncertainty that continues and its potential impact on patients.
About This Presenter
Nigel Rawson is a pharmacoepidemiologist and pharmaceutical policy researcher based in Saskatoon, Saskatchewan. He is also a Macdonald-Laurier Institute Senior Fellow, a Fraser Institute Senior Fellow and a Canadian Health Policy Institute Affiliate Scholar. Dr. Rawson has performed epidemiologic studies of prescription drug safety and pharmaceutical policy issues for over 40 years and published more than 140 peer-reviewed articles and book chapters as well as a monograph on drug safety. He has held academic positions in the United Kingdom and Canada. He has been a senior researcher in one of the largest US health insurer’s independent research centres, collaborating with the US Food and Drug Administration on drug safety studies, and GlaxoSmithKline’s only epidemiologist in Canada. Between 2012 and 2020, Dr. Rawson was President of Eastlake Research Group, the mission of which was to create data-driven responses to pharmaceutical policy issues. He continues this work as an independent researcher.
Thomas Müller, MD & Pharmacist, Head of Pharmaceuticals Dept Federal Joint Committee.
Pharma Pricing & Market Access Congress 2017
22 February 2017
London
Global HTA and pricing mechanisms
What can we learn about national medicines pricing and procurement?
Led by Janssen UK
Day One, Pop-up University 3, 16.00
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run.
Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London)
Event: HTAi 2019 Annual Meeting
Date: 18/06/2019
Location: Cologne, Germany
Is European market access becoming an incubator for rare disease development?...KateBenson18
FIECON's white paper 'Is European market access becoming an incubator for rare disease development?' explores the hypothesis that successful commercialisation in Europe is the biggest commercial opportunity for orphan drug manufacturers right now.
Hampered with faltering economies, squeezed budgets
and aging populations, the healthcare systems of Europe’s
major markets are firmly focused on providing cost-effective
outcomes. Although each country has specific market access
requirements, Health Technology Assessment (HTA) has
become an essential input into pricing and reimbursement
decisions and clinical guidance on the use of innovative
technologies across Europe.
Though HTA practices differ across and within national
boundaries, specific themes have emerged.In particular,
demands for evidence of clinical and/or economic benefit on
new health technologies are increasing.
Pricing and reimbursement negotiations are becoming
increasingly difficult, as cost-containment strategies—
including reference pricing, limiting reimbursement for
drugs assessed to lack cost-effectiveness, and retroactively
assessing drugs already on the market—are being
implemented in various ways across Europe.
This document has been put together with our leading market access experts compiled together from number of primary research published by our team recently.
Feel free to reach out on msheikh@teamdrg.com if you would like to talk more about our analysis in this space and how we could support with any specific questions you may have.
About US: DRG's Research and Data portfolio delivers industry-leading primary research and insights. We provide our customers with a baseline for market intelligence.
This presentation by Duncan Matthews was made during the Workshop on Recent Challenges in Competition and IP in Pharmaceutical Markets on 26 February 2019. More material on the workshop can be found at www.oecd.org/daf/competition/workshop-on-recent-challenges-in-competition-and-ip-in-pharmaceutical-markets.htm
Jan 31, 2018 How to Ensure Patient-Centred Pharmacare is Cost-Effective Healthcare
A Consultation on Patented Medicine Prices Review Board & Biologic Medicines
This presentation by Italy was made during a workshop on “Recent Challenges in Competition and IP in Pharmaceutical Markets” held by the OECD in Paris on 26 February 2019. More papers and presentations on the topic can be found out at oe.cd/2tD
The Regulatory Policy Institute, based in Oxford, holds an annual conference on competition and regulation. At this year’s conference, OHE’s Jon Sussex described how the prescription medicines market in England is regulated for innovation.
The regulatory problem for the pharmaceutical market is different from that for utilities markets, transport, financial services and indeed markets for all other types of goods and services. The source of the regulatory problem for prescription medicines in the NHS is that the consumer (patient) neither decides which medicine is prescribed nor is responsible for paying for it. For other goods and services, the consumer decides and pays, as well as consumes. In the pharmaceutical market under the NHS, it is the payer who effectively decides the value of an innovation, not the patient.
The cost and risk in drug development are high. To determine how best to target its R&D efforts, the pharmaceutical industry needs clear signals about what innovation the health care payer, the NHS, values. The recent history of such signalling has been dominated in England by the actions of the National Institute for Health and Care Excellence (NICE), whose assessments also have considerable influence internationally. Moreover, although England represents only 2% of the world pharmaceutical market, its prices are use as a reference for pricing in other markets.
How NICE expresses the value of medicines can be viewed as a mean of regulating innovation. NICE always has based its decisions about value on the incremental cost to the tax-funded health and social care services of the additional quality-adjusted life years a new medicine offers to patients. During the last year, NICE has been consulting on ways to broaden its assessment of value, particularly on whether to take account of the burden of disease and wider societal impacts beyond QALYs. The decisions have not yet been made and the signal to potential pharmaceutical innovators remains fuzzy.
Join Bill Dempster & guests Louise Binder & Martine Elias as they discuss the updates to the federal pharmaceutical price reform proposal, how patient leaders are responding and what steps they are taking to ensure that patients are being heard by decision makers.
This presentation by the French Competition Authority was made during a workshop on “Recent Challenges in Competition and IP in Pharmaceutical Markets” held by the OECD in Paris on 26 February 2019. More papers and presentations on the topic can be found out at oe.cd/2tD
Following the cancellation of most of the federal government’s proposed changes to the Patented Medicine Prices Review Board’s regulations, questions remain about how the Board will proceed in the future. The webinar will review the original changes and the one that remains. The topic will be discussed through the lens of a global pharmaceutical executive’s decision-making about whether to launch a new rare disorder drug in Canada in the next 12-18 months. Finally, we will chat about the uncertainty that continues and its potential impact on patients.
About This Presenter
Nigel Rawson is a pharmacoepidemiologist and pharmaceutical policy researcher based in Saskatoon, Saskatchewan. He is also a Macdonald-Laurier Institute Senior Fellow, a Fraser Institute Senior Fellow and a Canadian Health Policy Institute Affiliate Scholar. Dr. Rawson has performed epidemiologic studies of prescription drug safety and pharmaceutical policy issues for over 40 years and published more than 140 peer-reviewed articles and book chapters as well as a monograph on drug safety. He has held academic positions in the United Kingdom and Canada. He has been a senior researcher in one of the largest US health insurer’s independent research centres, collaborating with the US Food and Drug Administration on drug safety studies, and GlaxoSmithKline’s only epidemiologist in Canada. Between 2012 and 2020, Dr. Rawson was President of Eastlake Research Group, the mission of which was to create data-driven responses to pharmaceutical policy issues. He continues this work as an independent researcher.
The Canadian Cancer Survivor Network is pleased to offer a webinar titled “Health Canada calls for new tools to control drug prices: what will it mean for patients?”. This webinar will summarize the various pharmaceutical pricing reforms recently announced by federal health minister Dr. Jane Philpott and examine their potential effects on patient access to new innovations.
This engaging webinar will help you learn more about the Patented Medicine Prices Review Board and the impact of their proposed price review reforms. The webinar was moderated by 3Sixty Public Affairs’ Bill Dempster, who was joined by a panel of experts.
Former PMPRB staff member Neil Palmer analyzed the government’s perspectives on the proposed reforms. Carole Watson from Janssen presented a case study outlining the effects of the proposals on a pharmaceutical manufacturer’s decision making regarding the launch of a new cancer medicine and Martine Elias, Executive Director of Myeloma Canada, provided input on the proposed reforms from a patient leader perspective.
A moderated Q&A session allowed participants to provide their perspectives and questions on how the proposed pricing reforms might impact the availability of new innovative treatments in this country.
This is the first in a series of eight CCSN webinars on health technology assessment and drug approval. Stay tuned for further webinars.
Does Price Discrimination Have a Place in Pharmaceutical Pricing in Developin...Office of Health Economics
At iHEA 2013, OHE's Adrian Towse participated in a session on implementing differential pricing schemes. He discussed the role of price discrimination strategies, including the use of discounts, access programmes and risk sharing agreements in increasing the number of patients who can benefit from new medications in LMICs. Real life examples illustrated differential pricing schemes between and within countries and provided background for exploring feasibility—particularly about how options relying on confidentiality and negotiation compare with those based on collaborative international agreement about how price differentiation is developed and implemented.
This presentation by Pedro CARO DE SOUSA from the OECD Competition Division was made during the discussion “Excessive Pricing in Pharmaceuticals” held at the 130th meeting of the OECD Competition Committee on 28 November 2018. More papers and presentations on the topic can be found out at oe.cd/exph.
IHS Life Sciences Risk Sharing Workshop presentation shortIHS
Presentation given by Milena Izmirlieva , Senior Manager, Research Life Sciences, IHS at the 2015 CBI Reimbursement and Contracting conference in Philadelphia
Collaborating for Sustainable Water Management in the Oil and Gas IndustryIHS
Sarah Fletcher, Senior Research Analyst at IHS, presents at the 23rd Annual World Water Week, September 2-6, 2013 in Stockholm Sweden. World Water Week is the preeminent water conference for academic research on water. Sarah’s presentation, “Collaborating for Sustainable Water Management in the Oil and Gas Industry,” is part of an entire workshop on linking science, practice and policy under increasing complexity and uncertainty. www.ihs.com
IHS Goldfire is software that helps engineers, scientists and researchers to develop, maintain and produce breakthrough products.
Powered by world-class semantic search technology, IHS Goldfire transforms internal
and external information into actionable innovation intelligence.
IHS Goldfire helps organizations identify new markets, develop new products, mitigate risk and drive efficiencies.
IHS Analysis - Beirut Bombing - Hizbullah Targeted by MilitantsIHS
On 9 July, as many as 37 people were wounded in a vehicle-borne improvised explosive attack in Bir al-Abed, a Hizbullah stronghold in the south of Lebanon’s capital Beirut. The attack followed a series of threats in recent days by Syria-based militant Islamist groups to target Hizbullah areas in Lebanon.
Three states in southern Somalia are keen to become an autonomous region known as Jubbaland. IHS examines why the central Somali government opposes these plans, despite initially backing the idea.
Naval participation in counter-piracy operations around the Horn of Africa has been a success, but does this mean a long-term commitment from governments, or will a change in priorities mean that they leave before the situation is solved? IHS Jane's Defence Weekly Naval Editor Dr Lee Willett examines the issues.
With the Obama Administration’s pivot to the Asia-Pacific region, IHS attended the Pacific Operational S&T Conference and Exhibition on 5-8 March in Honolulu, Hawaii, for an update on US Pacific Command’s (PACOM) priorities and challenges.
This presentation provides selected IHS analysis of the event, its themes, outcomes and implications.
What You Need To Know About The Year Ahead In Africa And The Middle East - IH...IHS
International affairs always hold the potential to surprise, but despite the myriad permutations that surround this volatile region there are firm, fixed events – elections, military exercises, international conferences – and ongoing strategic trends and pressures that provide a static framework around which events are likely to unfold.
This IHS white paper sketches out the themes, issues and potential flashpoints that could come to define 2013 in this part of the world.
IHS Analysis - Sub-Saharan Africa Defence Budget Trends - December 2012IHS
The endurance of the global financial crisis has meant the economies of the Europe and North America have continued to struggle with slow export growth and significant fiscal challenges. As traditional Western defence markets fail to recover, new opportunities are being sought in territories previously viewed as unviable. Senior Analysts from IHS Jane’s Defence Budgets examine one of these potential markets – Sub-Saharan Africa – to determine the significance of the market.
North Korea has successfully launched its Unha-3 SLV and put a satellite into orbit, US officials have confirmed. Seoul and Washington condemned the launch, which is widely seen as a part of North Korea’s ICBM programme, while China expressed ‘regret’. IHS examines the impact and regional implications.